News

By analyzing just a drop of blood, this microchip gives researchers quicker-than-ever insight into how a person’s antibodies are interacting with a virus or other pathogen.

Scripps Research scientists’ new approach combines two immune-activating molecules known as adjuvants.

CLBR001 + ABBV-461 is a novel, investigational, two-part, switchable chimeric antigen T cell (sCAR-T) immunotherapy designed to treat solid tumors.

Cell-based therapy with roots at Scripps Research offers new hope for patients with macular telangiectasia type 2.

Scripps Research’s insights into sex-based differences in brain chemistry could guide personalized treatment strategies for alcohol use disorder.

More than 70% of the drugs identified by artificial intelligence extended the lifespan of C. elegans worms.

Certain antibodies blocked nearly 70% of HIV strains, including those typically hard to target.

Chi-Huey Wong Laboratories for Biomedical Research recognized for sustainable construction.

The ceremony represented the largest graduating class since the doctoral program’s inception in 1989.

President and CEO Pete Schultz is honored for expanding the genetic code and the development and application of large scale “diversity-based” approaches to the discovery of novel proteins, drugs and modern materials.

Researchers show that mpox circulated among humans in Nigeria for eight years before the international outbreak, highlighting the need for improved surveillance.

North American and African clinical trials led by Scripps Research, IAVI and additional collaborators across the U.S. and Africa mark progress toward an effective HIV vaccine.

Breakthrough from Scripps Research, the San Diego Zoo Wildlife Alliance, Max Planck Institute and other collaborators paves way for stem cell-based reproduction.

Latest book by Scripps Research executive vice president guides readers through medical breakthroughs that are primed to extend healthspan

Scripps Research scientists used computer modeling to illustrate how antibodies use fatty molecules known as lipids to recognize the HIV virus.

Scripps Research and Georgia Institute of Technology scientists’ discovery could help understand how life evolved on Earth and lead to better biofuel production.

Scripps Research scientists find that apremilast, an FDA-approved anti-inflammatory drug, reduced both drinking and pain sensitivity in preclinical models of alcohol use disorder.

Scripps Research scientists discover that a higher ratio of antibodies to viral protein helps engage two specific types of immune cells.

Scripps Research scientists developed a model that more accurately identifies patients at risk of coronary artery disease and can inform tailored treatment.

New insights from Scripps Research could advance phage therapies for the world’s deadliest bacteria—including drug-resistant strains.

Innovative cellular therapy has potential to treat patients with lupus, systemic sclerosis, myositis and RA without chemotherapy-induced immune suppression.

Scripps Research and aTyr Pharma scientists have revealed how the protein HARSWHEP calms inflammation associated with sarcoidosis.

Scripps Research scientists reveal that microRNAs guide the development of Purkinje cells, a rare type of neuron linked to neurodevelopmental disorders.

Researchers reprogrammed a botulinum toxin protease to selectively break down disease-causing proteins in human cells, providing proof of concept for developing new therapies for a wide range of illnesses.